CACNA1G and melanoma: These describe the involvement of TTCCs in melanoma progression and as a prognostic biomarker, Cav3.1 upregulation in BRAFV600E-mutant melanomas, and further involvement in the acquisition of resistant mechanisms to conventional treatments (Figure 2) [19,20,21,22].